<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00335179</url>
  </required_header>
  <id_info>
    <org_study_id>1467-IMIQ</org_study_id>
    <nct_id>NCT00335179</nct_id>
  </id_info>
  <brief_title>Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream</brief_title>
  <official_title>Double-Blind, Vehicle-Controlled Study to Evaluate Cellular and Molecular Events During Four Weeks of Treatment for Actinic Keratosis With Aldara (Imiquimod) Cream, 5%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Graceway Pharmaceuticals, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Graceway Pharmaceuticals, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of actinic keratosis with imiquimod cream is expected to cause changes in the genes
      that are turned on, and turned off, by skin cells. Some of the drug induced changes in skin
      cells should also be visible using a special microscope. This study examines both types of
      changes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study was to assess apoptosis by examining the gene expression
      profiles of actinic keratosis (AK) lesions that were treated with imiquimod 5% cream or
      vehicle cream once daily 3 times per week for 4 weeks. Secondary objectives were to assess
      the utility of confocal microscopy (CM) to visually track cellular response to treatment with
      study cream compared with clinical and histological evaluations, and to evaluate the safety
      of treatment with imiquimod in subjects with AK on the balding scalp.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">July 2003</completion_date>
  <primary_completion_date type="Actual">July 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gene expression profiling of treated lesions</measure>
    <time_frame>weeks 1, 2, and 4, and at 4 weeks post-treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Confocal microscopic evaluation before, during and post treatment</measure>
    <time_frame>weeks 1, 2, 4 and at 4 weeks post-treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Imiquimod cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imiquimod 5% cream containing 12.5 mg of imiquimod per 250 mg of cream Applied 3 times per week for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle cream 250 mg Applied 3 times per week for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aldara (imiquimod 5% cream)</intervention_name>
    <description>Imiquimod 5% cream containing 12.5 mg of imiquimod per 250 mg of cream</description>
    <arm_group_label>Imiquimod cream</arm_group_label>
    <other_name>imiquimod cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle cream</intervention_name>
    <description>Vehicle cream in 250 mg</description>
    <arm_group_label>Vehicle cream</arm_group_label>
    <other_name>placebo cream</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have actinic keratoses on balding scalp

          -  Discontinuation of tanning bed use

          -  Discontinuation of moisturizers

          -  Avoidance of retinol products

        Exclusion Criteria:

          -  Uncontrolled, clinically significant medical condition

          -  Dermatologic disease other than actinic keratosis in treatment area
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>TC Meng, MD</last_name>
    <role>Study Director</role>
    <affiliation>Graceway Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Torres A, Storey L, Anders M, Miller RL, Bulbulian BJ, Jin J, Raghavan S, Lee J, Slade HB, Birmachu W. Microarray analysis of aberrant gene expression in actinic keratosis: effect of the Toll-like receptor-7 agonist imiquimod. Br J Dermatol. 2007 Dec;157(6):1132-47. Epub 2007 Oct 18.</citation>
    <PMID>17944981</PMID>
  </reference>
  <reference>
    <citation>Torres A, Storey L, Anders M, Miller RL, Bulbulian BJ, Jin J, Raghavan S, Lee J, Slade HB, Birmachu W. Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream. J Transl Med. 2007 Jan 26;5:7.</citation>
    <PMID>17257431</PMID>
  </reference>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2006</study_first_submitted>
  <study_first_submitted_qc>June 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2006</study_first_posted>
  <last_update_submitted>July 22, 2010</last_update_submitted>
  <last_update_submitted_qc>July 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>James Lee, MD</name_title>
    <organization>Graceway Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Actinic keratosis</keyword>
  <keyword>AK</keyword>
  <keyword>imiquimod</keyword>
  <keyword>confocal microscopy</keyword>
  <keyword>gene microarray</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

